pSivida (NASDAQ:PSDV) is set to announce its earnings results before the market opens on Wednesday, February 7th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter.
pSivida (NASDAQ:PSDV) last issued its earnings results on Tuesday, November 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.15). The business had revenue of $0.39 million during the quarter, compared to analyst estimates of $0.74 million. pSivida had a negative return on equity of 139.56% and a negative net margin of 226.31%. On average, analysts expect pSivida to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of pSivida (NASDAQ:PSDV) opened at $1.20 on Wednesday. The stock has a market capitalization of $54.31, a P/E ratio of -2.61 and a beta of 1.34. pSivida has a 52 week low of $1.02 and a 52 week high of $2.45.
WARNING: This piece of content was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/31/psivida-psdv-set-to-announce-quarterly-earnings-on-wednesday.html.
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with MarketBeat.com's FREE daily email newsletter.